PACAP suppresses dry eye signs by stimulating tear secretion

Nakamachi, T; Ohtaki, H; Seki, T; Yofu, S; Kagami, N; Hashimoto, H; Shintani, N; Baba, A; Mark, L [Márk, László (Tömegspektrometria), szerző] MTA-PTE Humán Reprodukciós Kutatócsoport (PTE / KCS); Lanekoff, I; Kiss, P [Kiss, Péter (Neuroanatómia), szerző] Anatómiai Intézet (PTE / ÁOK); Farkas, J [Farkas, József (Anatómia), szerző] Anatómiai Intézet (PTE / ÁOK); Reglodi, D [Reglődi, Dóra (Idegtudományok), szerző] MTA-PTE Lendület PACAP Kutatócsoport (PTE / KCS); Shioda, S

Angol nyelvű Tudományos Szakcikk (Folyóiratcikk)
Megjelent: NATURE COMMUNICATIONS 2041-1723 7 Paper: 12034 , 13 p. 2016
  • SJR Scopus - Biochemistry, Genetics and Molecular Biology (miscellaneous): D1
Azonosítók
Szakterületek:
    Dry eye syndrome is caused by a reduction in the volume or quality of tears. Here, we show that pituitary adenylate cyclase-activating polypeptide (PACAP)-null mice develop dry eye-like symptoms such as corneal keratinization and tear reduction. PACAP immunoreactivity is co-localized with a neuronal marker, and PACAP receptor (PAC1-R) immunoreactivity is observed in mouse infraorbital lacrimal gland acinar cells. PACAP eye drops stimulate tear secretion and increase cAMP and phosphorylated (p)-protein kinase A levels in the infraorbital lacrimal glands that could be inhibited by pre-treatment with a PAC1-R antagonist or an adenylate cyclase inhibitor. Moreover, these eye drops suppress corneal keratinization in PACAP-null mice. PACAP eye drops increase aquaporin 5 (AQP5) levels in the membrane and pAQP5 levels in the infraorbital lacrimal glands. AQP5 siRNA treatment of the infraorbital lacrimal gland attenuates PACAP-induced tear secretion. Based on these results, PACAP might be clinically useful to treat dry eye disorder.
    Hivatkozás stílusok: IEEEACMAPAChicagoHarvardCSL
    2019-12-13 01:53